Insmed

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Insmed reports 23% revenue growth and successful ASPEN study enrollment

Insmed's strong financial performance and successful ASPEN study enrollment position the company for future growth. While operational costs and gross to net pose challenges, the robust pipeline and revenue guidance present growth opportunities.

Insmed Achieves Record Sales and Raises Revenue Guidance for 2023

Insmed's Q2 2023 performance reflects robust sales growth, strengthened revenue guidance, and a focus on advancing R&D initiatives. The company's emphasis on corporate responsibility and positive work environment adds to its overall appeal. However, challenges in business development and market dynamics in Japan require careful consideration. Anticipated data releases and clinical trial updates present promising growth prospects for the company.

Insmed reports record-setting revenues for ARIKAYCE and advances late-stage respiratory portfolio

Insmed's Q3 2023 earnings call showcased strong financial performance, particularly with record-setting revenues for ARIKAYCE and promising trial results for ARIKAYCE and brensocatib. The company's late-stage respiratory portfolio instills confidence, and its collaboration with Google Cloud reflects a forward-looking approach. However, potential financial challenges and the need for continued development in the DMD program are areas to monitor. Overall, the company is well-positioned to capitalize on opportunities in its pipeline and market access initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BRIDGEWATER, N.J. , April 25, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first-quarter 2024 financial results on Thursday, May 9, 2024.

Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024

BRIDGEWATER, N.J. , April 5, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to seven new employees.

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

—Additional Data from ARISE Study Evaluating the Impact of ARIKAYCE on Microbiologic Outcomes in Patients with Newly Diagnosed or Recurrent MAC Lung Disease to be Presented as Late-Breaker— —Data to be Presented from ARISE Examining Change in Patient-Reported Respiratory Symptoms— BRIDGEWATER, N.J. , March 27, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will present nine abstracts from across its respiratory portfolio at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024, in San Diego.

Insmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference

BRIDGEWATER, N.J. , Feb. 29, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following investor conferences: The TD Cowen 44th Annual Health Care Conference in Boston on Monday, March 4, 2024, at 2:50 p.m.

Insmed To Present at Three March Conferences

— New survey reveals the prevalence of "Unseenism," which can be described as a social phenomenon where gender and age biases can leave some patients feeling overlooked or unheard, in healthcare — — 58% of women who chose not to speak up during a visit with their doctor said it was because their health concerns were previously ignored — — Insmed's educational initiative "Speak Up in BE" aims to bring hope, education, and a sense of belonging to bronchiectasis (BE) patients who are feeling unseen — BRIDGEWATER, N.J. , Feb. 28, 2024  Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced its involvement with award-winning actress Jane Seymour to raise awareness of gender and age biases in healthcare.

Actress Jane Seymour and Insmed Raise Awareness of "Unseenism" and Empower People to Speak Up When It Comes to Their Health

Insmed Incorporated (INSM) Q4 2023 Earnings Call Transcript

Insmed (INSM) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $1.20 per share a year ago.

Insmed (INSM) Reports Q4 Loss, Misses Revenue Estimates

—Topline Data from the Phase 3 ASPEN Trial of Brensocatib in Adult Patients with Bronchiectasis Remain on Track to Read Out in the Latter Part of Second-Quarter 2024— —Enrollment in the Phase 2 Study of TPIP in Patients with PH-ILD Completed in November 2023; Topline Data Expected in Second-Quarter 2024 Ahead of the ASPEN Readout— —Company Ends 2023 With $780 Million of Cash, Cash Equivalents, and Marketable Securities, Providing Runway Beyond the Expected ASPEN Readout— — ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $83.7 Million for Fourth-Quarter and $305.2 Million for Full-Year 2023, Reflecting 24% Annual Growth and Exceeding the Upper End of Full-Year 2023 Guidance Range— —Company Reiterates Sales Guidance for 2024 Global ARIKAYCE Revenues in the Range of $340 Million to $360 Million, Reflecting Double-Digit Growth Compared to 2023— BRIDGEWATER, N.J. , Feb. 22, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.

Insmed Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Business Update

Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?

BRIDGEWATER, N.J. , Feb. 8, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its fourth-quarter and full year 2023 financial results on Thursday, February 22, 2024.

Insmed to Host Fourth-Quarter and Full Year 2023 Financial Results Conference Call on Thursday, February 22, 2024

—ARIKAYCE® (amikacin liposome inhalation suspension) Delivers Full-Year 2023 Revenues Exceeding the Upper End of Guidance Range with Unaudited Global Net Product Sales of Approximately $305.2 Million— —2024 Global ARIKAYCE Revenues Expected to be Between $340 Million and $360 Million, Reflecting Double-Digit Growth Compared to 2023— —Topline Data from the Phase 3 ASPEN Study of Brensocatib in Adult Patients with Bronchiectasis Remains on Track to Read Out in the Latter Part of Second-Quarter 2024— —Enrollment in the Phase 2 Study of TPIP in Patients with PH-ILD Completed in November 2023; Topline Data Expected in Second-Quarter 2024— BRIDGEWATER, N.J. , Jan. 5, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today provided an update on the Company's four pillars and outlook for 2024.

Insmed Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference

BRIDGEWATER, N.J. , Jan. 2, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the 42nd Annual J.P.

Insmed To Present at the 42nd Annual J.P. Morgan Healthcare Conference

BRIDGEWATER, N.J. , Nov. 29, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the Nasdaq 49th Investor Conference in London on Wednesday, December 6, 2023, at 8:30 a.m.

Insmed To Present at the Nasdaq 49th Investor Conference

BRIDGEWATER, N.J. , Nov. 8, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following investor conferences: The Stifel 2023 Healthcare Conference in New York on Tuesday, November 14, 2023, at 8:00 a.m.

Insmed To Present at Two November Conferences

— Company-wide day of service brings more than 700 employees together to volunteer in 25 locations throughout the U.S., Europe, and Japan — BRIDGEWATER, N.J. , Nov. 2, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today holds its second annual Global Day of Good, with hundreds of Insmed employees volunteering simultaneously in their respective communities.

Insmed Holds Second Annual Global Day of Good to Benefit Communities Across the Globe

-- Insmed Leads Science Top Employers List for Third Consecutive Year -- BRIDGEWATER, N.J. , Oct. 26, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it has earned the highest ranking in Science's 2023 Top Employers Survey.

Insmed Ranks No. 1 on Science's 2023 Top Biopharma Employers List

Insmed (INSM) came out with a quarterly loss of $1.10 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to loss of $1.09 per share a year ago.

Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates

—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $79.1 Million for the Third Quarter of 2023 Reflects Highest Quarter of Sales Since Launch and 17% Growth Compared to the Third Quarter of 2022— —Company Reiterates Full-Year 2023 Guidance Range for Global ARIKAYCE Revenues of $295 Million to $305 Million— —Insmed Shares Encouraging Blended and Blinded Dose Titration and Safety and Tolerability Data from the Phase 2 Studies of TPIP in PH-ILD and PAH, as Well as Blinded Pulmonary Vascular Resistance (PVR) Data from the PAH Study— —Topline Data from the Phase 3 ASPEN Trial of Brensocatib in Adult Patients with Bronchiectasis Remains on Track to Read Out in the Second Quarter of 2024— BRIDGEWATER, N.J. , Oct. 26, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a business update.

Insmed Reports Third-Quarter 2023 Financial Results and Provides Business Update

BRIDGEWATER, N.J. , Oct. 24, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company, today announced a collaboration with Google Cloud to transform the drug discovery, development, and commercialization landscape of the life sciences industry through the use of generative AI.

Insmed and Google Cloud Collaborate to Transform the Lives of Patients by Harnessing the Power of AI

Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Insmed (INSM) Report Negative Earnings Next Week? What You Should Know

BRIDGEWATER, N.J. , Oct. 12, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its third-quarter 2023 financial results on Thursday, October 26, 2023.

Insmed to Host Third-Quarter 2023 Financial Results Conference Call on Thursday, October 26, 2023

BRIDGEWATER, N.J. , Sept. 26, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at Chardan's 7th Annual Genetic Medicines Conference in New York, on Tuesday, October 3, 2023 at 2:00 p.m.

Insmed To Present at Chardan's 7th Annual Genetic Medicines Conference

Insmed is looking to broaden the use of its only approved therapy, Arikayce. The company had a record $72 million in revenue in the second quarter.

Why Shares of Insmed Are Soaring This Week

Insmed's (INSM) shares rise on positive data from the late-stage ARISE study evaluating Arikayce for newly infected lung disease caused by MAC.

Insmed (INSM) Up on Positive Data From MAC Lung Disease Study

BRIDGEWATER, N.J. , Sept. 6, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference in New York, on Monday, September 11, 2023 at 2:55 p.m.

News for Insmed Stock (INSM)